Drug Trial Radar · NCT00628628
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Jan 2008
Primary completion
May 2012
Study completion May 2012
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi
- First posted
- Mar 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: To determine the efficacy of rasburicase administered as a single dose followed by as needed dosing (investigational arm) as compared to fixed dosing for 5 days (standard treatment arm) in the treatment of patients at high risk or potential risk for tumor lysis syndrome. Secondary Objectives: 1. To evaluate the plasma uric acid area under the curve (AUC) from baseline through 7 days 2. To evaluate the incidence of renal insufficiency and electrolyte abnormalities. 3. To determine the safety and immunogenicity of rasburicase. 4. To evaluate the cost-effectiveness of the experimental treatment (investigational arm).
Conditions
- Tumor Lysis Syndrome
Interventions
As Needed RasburicaseDrug
.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
Fixed Dose RasburicaseDrug
.15 mg/kg IV Over 30 Minutes Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Plasma Uric Acid (UA) ResponseTime frame: First cycle of chemotherapy, up to 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UT MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.